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Linezolid (PNU-100766) and eperezolid (PNU- 
100592) belong to a new class of synthetic antimicro- 
bial agents called the oxazolidinones [l]. These agents 
are highly active against many clinically important 
Gram-positive bacteria including methicillin-resistant 
staphylococci, vancomycin-resistant enterococci and 
penicillin-resistant pneumococci with MIC90 values 
usually ranging from 0.5 to 4 mg/L [2,3]. Gram- 
negative aerobic microorganisms are generally not 
inhibited by these compounds. The oxazolidinones 
exhibit a unique mechanism of bacterial protein 
synthesis inhibition, resulting in mainly bacteriostatic 
activity [l]. 
Anaerobic bacteria are a common cause of serious 
infections. The anaerobic species which predominate 
in clinical infections include the Bacteroides fragilis 
group, Clostridium spp., Fusobacterium nucleatum and 
Peptostreptococcus spp. Treatment of anaerobic infections 
is often difficult, since many anaerobes are intrinsically 
resistant to certain antimicrobial agents such as amino- 
glycosides, trimethoprim, sulfamethoxazole, most 
quinolones and monobactams [4]. Resistance against 
tetracyclines is widespread, and many clinically import- 
ant anaerobes exhibit resistance against clindamycin and 
several p-lactam agents. Resistance against cefoxitin, 
imipenem and metronidazole has been reported, 
although it is uncommon. Drugs commonly used in 
the treatment of anaerobic infections are p-lactam 
compounds, clindamycin, metronidazole and chloram- 
phenicol [5]. 
The aim of the present study was to determine the 
in vitro activity of linezolid and eperezolid against 360 
anaerobic bacterial strains isolated from human 
infections. 
Three hundred and sixty anaerobic clinical isolates, 
including Peptostreptococcus spp. (50 strains), Propioni- 
bacterium acnes (30 strains), Clostridium pefringens (30 
strains), C .  dficile (50 strains), B. fragilis (50 strains), 
Bacteroides, Porphyromonas, and Prevotella spp. (100 
strains) and fusobacteria (50 strains), collected at the 
Huddinge University Hospital, Stockholm, Sweden 
were tested. All strains were identified by biochemical 
tests and gas-liquid chromatographic analyses of 
metabolic end products according to the techniques 
described by Summanen et al. [6]. The strains were 
cultured in prereduced yeast glucose medium or in 
prereduced chopped meat broth with glucose. Linezolid 
and eperezolid were obtained from Pharmacia & 
Upjohn Inc., Kalamazoo, MI, USA. Fresh dilutions of 
each compound were prepared daily. The antimicrobial 
agents were suspended and diluted according to the 
manufacturers’ instructions. Antimicrobial susceptibility 
tests were performed by the agar dilution method using 
PDM-ASM agar (Biodisk, Stockholm, Sweden), with 
the addition of 5% defibrinated horse blood. Anti- 
microbial concentrations from 0.008 to 128 mg/L were 
obtained by incorporation of each substance when 
preparing the agar plates. The inocula consisted of 
48-h broth cultures diluted in prereduced yeast 
glucose medium to a final inoculum of lo8 CFU/mL. 
Then, 1 .O-2.0 pL was applied to the agar plates with a 
modified Steers replicator, resulting in approximately 
lo3 CFU per spot. An agar plate without antimicrobial 
agent was always included as growth control. Agar 
plates were incubated in anaerobic jars (GasPak, BBL, 
Microbiology Systems, Cockeysville, MD, USA) for 
48 h at 37°C. The MIC was defined as the lowest 
concentration that inhibited growth of organisms on 
the agar plates. A barely visible haze or the appearance 
of a single colony was disregarded. Three control strains 
were used to monitor the antimicrobial susceptibility 
test: B. frdgilis ATCC 25285, B. thetaiotaomicron ATCC 
29741 and C. pefingens ATCC 13124. 
Ninety per cent of all tested PeptostreptococccuJ spp. 
(50 strains), Propionibacterium acnes (30 strains), C. 
perjringens (50 strains) and C. dficile (50 strains) were 
inhibited by 22 mg/L linezolid and eperezolid. 
Table 1 In vitro activity of linezolid and eperezolid against 
360 anaerobic bacterial strains 
Microorganism MIC (mg/L) 
(no. of isolates tested) 
and antimicrobial agent Range MICso MICro 
Pcptostreptococcus (50) 
Linezolid 
Eperezolid 
Propionibacterium acnes (30) 
Linezolid 
Eperezolid 
Ciostridium pefringens (50) 
Linezolid 
Eperezolid 
Clostridium dijiicile (50) 
Linezolid 
Eperezolid 
Bactrroidesjagilis (100) 
Linezolid 
Eperezolid 
Bacteroides, Porphyromonas, 
Preiatella (50) 
Linezolid 
Eperezolid 
Fusobacterium (30) 
Linezolid 
0.25-2.0 
0.25-1.0 
0.25-1.0 
0.5-1.0 
1.0-4.0 
1.0-2.0 
1.w2.0 
0.5-1.0 
2.0-4.0 
2.0-32 
0.25-8.0 
0.125-8.0 
0.25-8.0 
1.0 
0.5 
0.5 
0.5 
2.0 
2.0 
1 .0 
1 .0 
4.0 
8.0 
2.0 
2.0 
0.5 
2.0 
1 .o 
0.5 
1 .0 
2.0 
2.0 
2.0 
1 .0 
4.0 
16.0 
4.0 
8.0 
8.0 
Eperezolid 0.125-2.0 0.25 2.0 
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Linezolid showed higher activity (MICgo 4.0 mg/L) 
against B. jragilis (100 strains) compared to eperezolid 
(MICgo 16 mg/L). The MIC values (range, MIC50 and 
MICgo) for the 360 tested strains of linezolid and 
eperezolid are shown in Table 1. Strains with intrinsic 
resistance to conventional anti-anaerobe agents, includ- 
ing three C. d@le strains and one B. jagi l i s  strain 
resistant to clindamycin, seven €3. ,%@is strains resistant 
to cefoxitin, and one B. splunchnicus resistant to 
metronidazole, did not show any cross-resistance to the 
oxazolidinones. 
The results of the present study are in accordance 
with previous reports on in vitro susceptibility to 
linezolid and eperezolid of anaerobic microorganisms 
[3].  Oral administration of linezolid (400 mg PO) and 
eperezolid (1 000 mg PO) to healthy volunteers has 
earlier been reported to yield peak serum concentra- 
tions of 12.38 mg/L and 6.28 mg/L, respectively, while 
the trough concentrations were estimated to be 
7.9 mg/L and 1.62 mg/L, respectively [7]. These serum 
levels of linezolid are well in excess of the MICs €or 
anaerobic Gram-positive bacteria as well as for many 
anaerobic Gram-negative microorganisms. Concerning 
eperezolid, anaerobic Gran-positive bacteria are mainly 
susceptible to achieved serum levels. Linezolid has 
been reported to be active versus experimental B. -fiagilis 
soft tissue infections in mice [XI .  Future clinical studies 
will show the potential of the oxazolidinones in 
the treatment of anaerobic infections. In conclusion, 
the new oxazolidinones linezolid and eperezolid 
have excellent activity against Gram-positive anaerobic 
microorganisms, with linezolid also exhibiting activity 
against Bacteroides spp. These agents may be useful in 
the treatment and prophylaxis of anaerobic infections. 
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Agglutination kits for the identification of Staphylococcus 
aweus have been available for a number of years as an 
alternative to the coagulase test. The tube coagulase 
test, which detects the production of free coagulase, 
was considered to be the standard (sensitivity 95-98%) 
but it takes 4-34 h for completion [I 4. A more simple 
